New study aims to find best myeloma treatment for seniors
NCT ID NCT03829371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at which treatment works best for older adults (65+) with multiple myeloma who cannot have a stem cell transplant. It compares standard drug combinations with or without daratumumab, a targeted antibody. The goal is to find the best balance of benefits, side effects, and quality of life for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Torino, TO, 10126, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact